Questions About Cancer? 1-800-4-CANCER

Clinical Trial Results

Summaries of Newsworthy Clinical Trial Results

Soft Tissue Sarcoma Trial Results


  • Imatinib (Gleevec®) Reduces Cancer Recurrence in Patients with Surgically Removed GIST
    (Posted: 06/25/2007, Updated: 05/19/2009) - Patients with localized gastrointestinal stromal tumors (GIST) who took imatinib (Gleevec®) after surgical removal of the primary tumor were less likely to have a recurrence of their cancer, according to findings presented at the 2007 ASCO meeting in Chicago.
  • Gleevec Decreases Cancer Recurrence for Patients with Primary Gastrointestinal Stromal Tumor
    (Posted: 04/12/2007) - Preliminary results from a large, randomized, placebo-controlled clinical trial for patients with primary gastrointestinal stromal tumor, a type of tumor usually found in the stomach or small intestine, showed that patients who received imatinib mesylate (Gleevec ®) after complete removal of their tumor were significantly less likely to have a recurrence of their cancer compared to those who did not receive imatinib.